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DNA repair enzymes repair DNA damaged by platinum agents and ionising radiation. Single nucleotide polymorphisms (SNPs) in
DNA repair genes modulate the repair capacity and might affect response and prognosis following platinum-based
chemoradiotherapy (CRT). We investigated associations between the functional SNPs in DNA repair genes and response and
survival in muscle-invasive bladder cancer patients treated with CRT to determine the predictive value of the SNPs in patient
selection for bladder conservation therapy. The study group comprised 78 patients who underwent CRT for transitional cell
carcinoma of the bladder. Single nucleotide polymorphisms in xeroderma pigmentosum complementation groups C (Lys939Gln, A/
C), D (XPD; Lys751Gln, A/C), and G (Asp1104His, G/C), and X-ray repair cross-complementing groups 1 (XRCC1; Arg399Gln, G/
A) and 3 (Thr241Met, T/C) genes were genotyped. Combined genotypes with at least one variant allele in XPD or XRCC1 were
significantly associated with improved cancer-specific survival compared with remaining groups (P¼0.009). In multivariate analysis,
only the combined XPD and XRCC1 genotypes were independently associated with cancer-specific survival (P¼0.04). The
association was stronger in stage T3/T4 patients (P¼0.0008). These results suggest that combined XPD and XRCC1 genotypes
might be prognostic factors in muscle-invasive bladder cancer patients treated with CRT.
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The complex system of DNA repair enzymes plays a vital role in
protecting the genome from the consequences of mutagenic
exposure (Hoeijmakers, 2001). At least four pathways of DNA
repair: base excision repair (BER), nucleotide excision repair
(NER), double-strand-break (DSB) repair and mismatch repair,
operate on specific types of damaged DNA and each involves
numerous molecules (Goode et al, 2002). There are several
common single nucleotide polymorphisms (SNPs) in genes
encoding DNA repair enzymes and many case–control studies
have examined the relationship between SNPs and susceptibility to
different types of cancer (Goode et al, 2002). Some of the SNPs in
DNA repair genes reportedly result in a subtle structural alteration
of the repair enzyme and modulation of the repair capacity (Lunn
et al, 1999; Spitz et al, 2001; Matullo et al, 2003; Vodicka et al,
2004).
NER is an essential pathway of DNA repair and the only known
mechanism in mammalian cells for the removal of bulky, helix-
distorting DNA adducts produced by platinum agents (Park et al,
2001). Moreover, DNA damaged by ionising radiation is repaired
mainly by the BER pathway and by homologous recombination
repair (HRR) and nonhomologous end-joining repair, which are
types of DSB repair (Hu et al, 2001; Khanna and Jackson, 2001).
Modulation of repair capacity by the SNPs in DNA repair genes
might therefore affect response and prognosis following platinum-
based chemoradiotherapy (CRT) for cancer. The associations
between SNPs and clinical response or prognosis have been
reported in patients with lung or colorectal cancer treated with
platinum-based chemotherapy or radiotherapy (Park et al, 2001;
Gurubhagavatula et al, 2004; Ryu et al, 2004; Stoehlmacher et al,
2004; Zhou et al, 2004; Yoon et al, 2005).
Although the gold standard for the treatment of muscle-invasive
urinary-bladder cancer is radical cystectomy followed by urinary
diversion, this procedure is likely to impair the quality of life of the
patient (Ro ¨del et al, 2002). In many areas of cancer treatment, the
trend in the 1990s was aimed at organ conservation using
combined chemotherapy and radiation with or without conserva-
tive local surgery (Shipley et al, 2003). In invasive bladder cancer,
several groups have reported the value of combined-modality
therapy, including transurethral resection (TUR), radiation
therapy, and platinum-based systemic chemotherapy (Ro ¨del
et al, 2002; Shipley et al, 1998, 2003). With these programs,
cystectomy is reserved for patients with an incomplete response
or local relapse after combined-modality treatment. Five-year
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ssurvival rates in the range of 50–65% have been published in these
series, and approximately three quarters of the surviving patients
maintained their own bladders (Tester et al, 1996; Kachnic et al,
1997; Dunst et al, 2001). However, combined-modality therapy
may not only be potentially harmful but also diminish survival as a
result of the delay in cystectomy for some patients with
nonresponding bladder tumours. Thus, predictors of response
and prognosis after therapy that help determine appropriate
patients for bladder preservation are sorely required.
In the current study, we investigated the associations between
functional SNPs in DNA repair genes (xeroderma pigmentosum
complementation groups C (XPC), D (XPD), and G (XPG)
(involved in NER), and X-ray repair cross-complementing groups
1 (XRCC1) (involved in BER), and 3 (XRCC3) (involved in HRR))
and the clinical response and survival in patients with locally
invasive bladder cancer treated with platinum-based CRT to
determine the predictive value of the SNPs in patient selection for
bladder conservation therapy.
MATERIALS AND METHODS
Patients
The ethical review committee of Yamaguchi University School of
Medicine approved this study. The study group comprised 78
patients who underwent CRT for locally muscle-invasive (T2-
4N0M0) or high-risk superficial (T1G3) urinary-bladder cancer at
the Department of Urology, Yamaguchi University School of
Medicine, Ube, Japan, from January 1995 to October 2004. The
median age was 68 years (range, 29–89 years) and patients
included 59 men (75.6%) and 19 women (24.4%). Before treatment,
all patients underwent tumoural and random-mucosal biopsies of
the bladder transurethrally and a computerised tomography (CT)
scan for staging. Patients were staged according to the TNM
staging system of the UICC (1992): five (6.4%) were stage T1G3, 35
(44.9%) stage T2, 30 (38.5%) stage T3, and eight (10.3%) stage T4.
All bladder tumours were histopathologically confirmed as
transitional cell carcinoma (TCC). Of the 78 tumours, 69 showed
TCC only, five showed an adenocarcinoma component, and four
showed squamous differentiation. The tumours were graded
according to the WHO classification: the majority (n¼60,
76.9%) were grade 3 and the remaining 18 (23.1%) were grade 2.
CRT
All patients received combined platinum-based systemic che-
motherapy and radiation therapy. In most patients, the regimen
(based on Shipley’s method with slight modification) (Shipley
et al, 1987) for one cycle was cisplatin (70mgm
 2) on day 1, with
radiation administered by Liniac to the true pelvis at 1.8 grays (Gy)
per fraction from day 2 to day 5 in the first week, and on five
consecutive days in the second week (Matsumoto et al, 2004a). The
photon energy of the Liniac was 10MV and patient-specific target
volume was defined by CT planning. This therapy was carried out
one to three times every 14 days. At completion of one cycle of
CRT, patients were treated with 70mgm
 2 cisplatin and irradia-
tion of the basic target at 16.2Gy. Although we tried to perform
three cycles of CRT where possible, the treatment was halted in
patients who received one or two cycles of therapy and showed
persistent side effects such as nausea, vomiting, diarrhea, or
pancytopenia for 2 weeks or who refused to continue with CRT.
The median total doses of cisplatin and radiation were 235mg
(range, 120–400mg) and 48.6Gy (range, 30–60.4Gy), respectively.
At 4 weeks after the completion of CRT, patients were assessed
for response by random-mucosal biopsy or TUR and a CT scan.
Patients with nonresponding tumours were referred for radical or
partial cystectomy: salvage cystectomy was undertaken in 17
patients (21.8%). Patients with responding tumours underwent
complete resection of the cancer by TUR. A complete response
(CR) was defined as no residual tumour detected pathologically, a
partial response (PR) as a residual nonmuscle-invasive tumour,
and no change (NC) as a residual muscle-invasive tumour.
Complete response was observed in 35.9% (28 of 78), PR in
43.6% (34 of 78), and NC in 20.5% (16 of 78). Twelve patients with
residual carcinoma in situ received intravesical instillation of BCG.
Cystoscopic examination followed by washing cytology was carried
out every 3 months for the first 5 years and every 6 months
thereafter. Complementary examinations, including chest X-rays
and/or CT scans, were carried out every 6 months. The median
duration of follow-up was 45 months (range, 2–124 months). Of
the 67 patients who achieved a state of no evidence of disease after
combined-modality therapy, 37 (55.2%) had superficial or
invasive-local recurrence or distant metastasis. A total of 17
patients suffered cancer-related death during the follow-up.
DNA extraction and genotyping
Venous blood samples were collected from each patient before
tumour biopsies. Lymphocyte DNA was extracted using the
QIAamp DNA Mini Kit (VWR International, West Chester, PA,
USA) or GenTLE extraction kit (Takara, Tokyo, Japan). Single
nucleotide polymorphisms in XPC (Lys939Gln, A/C), XPD
(Lys751Gln, A/C), XPG (Asp1104His, G/C), XRCC1 (Arg399Gln,
G/A), and XRCC3 (Thr241Met, T/C) genes were genotyped using
polymerase chain reaction–restriction fragment length poly-
morphism (PCR–RFLP). The method, including primer sequences
and restriction endonucleases for each SNP, was described
previously (Sanyal et al, 2004; Sakano et al, 2006). Briefly, the
DNA fragments were amplified from 10ng of DNA in 10ml PCR
reactions containing 1.5mM MgCl2, 0.2mM each dNTP, 0.3U
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City,
CA, USA) and 0.3mM of each primer. The PCR products were
digested with the appropriate restriction endonucleases that
recognised and cut either wild-type or variant sequences at 371C
for at least 3h. The digested PCR products were electrophoresed
on 2% agarose gels and stained with ethidium bromide for
visualisation under UV light. In order to control the restriction
digestion of the PCR products, genotyping assays were randomly
repeated and results were checked for concordance. About 10% of
the amplified fragments were also randomly checked by direct
DNA sequencing and comparison of the PCR–RFLP and sequen-
cing results showed 100% concordance in all experiments (Kumar
et al, 2003; Sakano et al, 2003).
Statistical analysis
Relationships between genotypes of the DNA repair genes and
tumour stage, grade, response to CRT, and recurrence were
assessed using the w
2-test (with Yates’ correction) and the odds
ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI)
were calculated. Bonferroni correction was taken into considera-
tion because multiple comparisons were carried out. For this
correction, a P-value of p0.006 was considered statistically
significant. The outcome selected for this study was cancer-
specific survival, defined as the time from the start of CRT to the
date of death from muscle-invasive bladder cancer. Cancer-specific
survival was analysed by plotting Kaplan–Meier curves and the
survival probability distributions were compared using the log-
rank test. Categorical variables influencing survival were compared
using Cox proportional hazards regression. Data were processed
using JMP software (SAS Institute Inc., Cary, NC, USA), with
Po0.05 indicating statistical significance. Variables with Po0.05
in univariate analysis were also assessed for their relationship with
cancer-specific survival in multivariate analysis.
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sRESULTS
Genotypes of DNA repair genes and clinical prognostic
features
Genotype frequencies of SNPs in XPC, XPD, XPG, XRCC1, and
XRCC3 genes were found to be in Hardy–Weinberg equilibrium.
The variant allele frequencies for the SNPs were 44.4, 6.9, 59.1,
22.2, and 6.5%, respectively. The numbers of variant alleles for
XPD and XRCC1 were not associated with one another (P¼0.91;
w
2-test; Table 1). No associations were detected between the
genotypes and age or gender. None of the genotypes were
associated with histopathology of the tumours (TCC only, TCC
with adenocarcinoma element, or TCC with squamous cell
carcinoma element). None of the evaluated genotypes were
associated with tumour stage or grade (w
2-test (with Yates’
correction); Table 2). The relationships between the genotypes of
DNA repair genes and response to CRT and tumour recurrence or
metastasis are presented in Table 3. The genotypes were not
associated with response to CRT at 4 weeks after evaluation. There
were no relationships between the genotypes of XPC, XPD, XPG,
XRCC1, XRCC3, or combined XPD and XRCC1 genes and
recurrence during follow-up. The recurrence rate was significantly
lower in patients with greater numbers of total variant alleles both
in all DNA repair genes studied and in NER genes: XPC, XPD, and
XPG (43 compared with p3, RR: 0.70, 95% CI: 0.49–0.99,
P¼0.03; 42 compared with p2, RR: 0.66, 95% CI: 0.44–0.99,
P¼0.03; respectively; w
2-test). However, when the Bonferroni
correction for multiple comparisons was taken into consideration,
the recurrence rate was not significantly lower in those patients.
Genotypes of DNA repair genes and cancer-specific
survival
In univariate analysis using the Cox proportional hazards
regression model, XRCC1 genotypes, combined XPD and XRCC1
genotypes, and the number of total variant alleles in DNA repair
genes were significantly associated with cancer-specific survival
(RR: 0.51, 95% CI: 0.20–0.98, P¼0.04 for XRCC1; RR: 0.41, 95%
CI: 0.16–0.79, P¼0.006 for combined XPD and XRCC1; RR: 0.51,
Table 1 Distribution of XPD and XRCC1 genotypes
XRCC1 genotype (Arg399Gln, G/A)
XPD genotype
(Lys751Gln, A/C) GG GA AA
AA 40 16 5
AC 7 2 1
CC 0 0 0
P-value¼0.91.
Table 2 Relationship between genotypes of DNA repair genes and tumour stage and grade
Stage Grade
Genotype T1G3/T2 T3/T4 Odds ratio (95% CI) P-value 2 3 Odds ratio (95% CI) P-value
XPC (Lys939Gln, A/C)
AA 11 10 5 16
AC 19 18 1.04 (0.36–3.04) 0.94 8 29 1.13 (0.32–4.05) 0.89
CC 7 6 0.94 (0.24–3.77) 0.79 3 10 1.04 (0.20–5.34) 0.71
AC+CC 26 24 1.02 (0.37–2.82) 0.98 11 39 1.11 (0.33–3.70) 0.88
XPD (Lys751Gln, A/C)
a
AA 35 27 15 47
AC+CC 2 8 5.19 (1.02–26.43) 0.07 2 8 1.28 (0.24–6.68) 0.91
XPG (Asp1104His, G/C)
GG 6 6 3 9
GC 18 21 1.17 (0.32–4.26) 0.92 10 29 0.97 (0.22–4.30) 0.74
CC 15 11 0.73 (0.19–2.90) 0.93 5 21 1.40 (0.27–7.15) 0.98
GC+CC 33 32 0.97 (0.28–3.32) 0.79 15 50 1.11 (0.27–4.64) 0.82
XRCC1 (Arg399Gln, G/A)
a
GG 21 26 12 35
GA+AA 16 9 0.45 (0.17–1.23) 0.12 5 20 1.37 (0.42–4.46) 0.60
XRCC3 (Thr241Met, C/T)
a
CC 31 29 14 46
CT+TT 5 4 0.86 (0.21–3.50) 0.89 2 7 1.07 (0.20–5.72) 0.73
Combined XPD and XRCC1
XPD AA and XRCC1 GG 20 20 10 30
Other 17 15 0.88 (0.35–2.24) 0.79 7 25 1.19 (0.40–3.58) 0.76
Total variant alleles in DNA repair genes
p32 9 2 6 1 3 4 2
43 11 12 1.22 (0.46–3.22) 0.69 5 18 1.11 (0.35–3.59) 0.86
Total variant alleles in NER genes
b
p22 8 2 2 1 2 3 8
42 12 16 1.70 (0.67–4.32) 0.27 6 22 1.16 (0.38–3.52) 0.80
NER¼nucleotide excision repair.
aFor those polymorphisms with few homozygous variant alleles, only the combined results of the heterozygous and homozygous variant alleles
are shown.
bNER genes include XPC, XPD, and XPG.
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s95% CI: 0.20–0.95, P¼0.03 for variant alleles; Table 4), so patients
with XRCC1 GAþAA genotypes, with at least one variant allele in
XPD or XRCC1, and with more than 3 variant alleles in DNA repair
genes had improved cancer-specific survival. Cancer-specific
survival was plotted for the above-mentioned genotypes using
Kaplan–Meier survival curves (Figure 1A–C, respectively).
Combined genotypes with at least one variant allele in XPD or
XRCC1 were significantly associated with improved cancer-specific
survival compared with remaining groups (P¼0.009; log-rank
test). However, there were no significant differences with regard to
the XRCC1 genotypes or number of variant alleles in DNA repair
genes (P¼0.06 and P¼0.05, respectively; log-rank test).
Clinical variables were also assessed for their relationship with
cancer-specific survival (Table 4). In univariate analysis, tumours
with adenocarcinoma or squamous cell carcinoma elements, high-
dose radiation (X48.6Gy), and a nonresponse to CRT (NC) were
significantly associated with an unfavourable outcome (RR: 2.15,
95% CI: 1.13–3.65, P¼0.02 for other elements; RR: 2.56, 95% CI:
1.45–5.36, P¼0.0007 for radiation dose; RR: 1.75, 95% CI: 1.01–
2.89, P¼0.04 for response to CRT). In multivariate analysis
(model one) including all significant factors (other elements,
radiation dose, response to CRT, XRCC1 genotypes, and number
of total variant alleles in DNA repair genes), only high-dose
radiation was significantly associated with an unfavourable out-
come (RR: 2.00, 95% CI: 1.06–4.35, P¼0.03). When combined
XPD and XRCC1 genotypes were used instead of XRCC1 genotypes
and the number of variant alleles in the DNA repair genes in
multivariate analysis (model two), only the combined XPD and
XRCC1 genotypes were independently associated with cancer-
specific survival (RR: 0.50, 95% CI: 0.19–0.97, P¼0.04).
In stage T3/T4 patients, cancer-specific survival was plotted for
XRCC1 genotypes, combined XPD and XRCC1 genotypes, and the
number of variant alleles in DNA repair genes (Figure 2A–C,
respectively). All were significantly associated with cancer-specific
survival (P¼0.03, P¼0.001, and P¼0.04, respectively; log-rank
test). In multivariate analysis, the XRCC1 genotypes (model one)
and the combined XPD and XRCC1 genotypes (model two) were
independently associated with cancer-specific survival in stage T3/
T4 patients (RR: 0.0004, 95% CI: not calculated, P¼0.02; RR:
0.0003, 95% CI: 0.00–0.53, P¼0.0008, respectively; Table 5).
DISCUSSION
Previous reports have revealed significant associations between
XPD or XRCC1 gene polymorphisms and survival of lung or
colorectal cancer patients treated with platinum-based chemo-
therapy or radiotherapy (Park et al, 2001; Gurubhagavatula et al,
2004; Stoehlmacher et al, 2004; Yoon et al, 2005). Concerning
bladder cancer, Gu et al (2005) showed that the NER gene
Table 3 Relationship between genotypes of DNA repair genes and response to chemoradiotherapy and recurrence or metastasis
Response Recurrence
Genotype CR/PR NC Risk ratio (95% CI) P-value No Yes Risk ratio (95% CI) P-value
XPC (Lys939Gln, A/C)
AA 16 5 7 13
AC 27 10 1.12 (0.49–2.52) 0.79 16 14 0.63 (0.30–1.31) 0.20
CC 12 1 0.69 (0.42–1.11) 0.46 7 5 0.69 (0.38–1.26) 0.36
AC+CC 39 11 0.93 (0.40–2.15) 0.87 23 19 0.57 (0.27–1.24) 0.15
XPD (Lys751Gln, A/C)
a
AA 47 15 24 30
AC+CC 9 1 0.90 (0.75–1.06) 0.55 6 3 0.88 (0.71–1.08) 0.38
XPG (Asp1104His, G/C)
GG 9 3 5 5
GC 34 5 0.56 (0.19–1.62) 0.58 16 17 1.05 (0.35–3.10) 0.78
CC 18 8 1.22 (0.41–3.68) 0.98 9 14 1.36 (0.49–3.80) 0.84
GC+CC 52 13 0.79 (0.24–2.57) 40.99 25 31 1.20 (0.38–3.76) 0.97
XRCC1 (Arg399Gln, G/A)
a
GG 35 12 20 20
GA+AA 21 4 0.83 (0.59–1.18) 0.53 10 12 1.07 (0.74–1.54) 0.73
XRCC3 (Thr241Met, C/T)
a
CC 46 14 25 28
CT+TT 8 1 0.91 (0.77–1.09) 0.69 5 2 0.89 (0.74–1.08) 0.42
Combined XPD and XRCC1
XPD AA and XRCC1 GG 29 11 16 18
Other 27 5 0.75 (0.50–1.14) 0.23 14 14 0.95 (0.60–1.49) 0.82
Total variant alleles in DNA repair genes
p34 4 1 1 1 7 3 0
43 18 5 1.03 (0.72–1.49) 0.86 13 7 0.70 (0.49–0.99) 0.03
b
Total variant alleles in NER genes
c
p2 41 9 15 28
42 21 7 1.18 (0.74–1.88) 0.66 15 9 0.66 (0.44–0.99) 0.03
b
CR¼complete response; PR¼partial response; NC¼no change; NER¼nucleotide excision repair.
aFor those polymorphisms with few homozygous variant alleles, only the
combined results of the heterozygous and homozygous variant alleles are shown.
bDifferences not significant after application of Bonferroni correction as P-values are 40.006.
cNER genes include XPC, XPD, and XPG.
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sTable 4 Univariate and multivariate regression analyses for predicting cancer-specific survival in all bladder cancer patients treated with
chemoradiotherapy
Univariate model Multivariate model one Multivariate model two
Variable (n) Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value
Age (years)
p68 (41)
468 (37) 1.31 (0.81–2.15) 0.27
Gender
Men (59)
Women (19) 0.97 (0.52–1.64) 0.92
Tumour stage
T1G3/T2 (40)
T3/T4 (38) 1.61 (0.98–2.85) 0.06
Tumour grade
2 (18)
3 (60) 0.81 (0.50–1.44) 0.45
Histopathology
Pure TCC (69)
Other elements (9) 2.15 (1.13–3.65) 0.02 1.80 (0.83–3.47) 0.13 1.85 (0.84–3.58) 0.11
Cisplatin dose (mg)
o235 (37)
X235 (37) 1.27 (0.78–2.10) 0.34
Radiation dose (Gy)
o48.6 (38)
X48.6 (40) 2.56 (1.45–5.36) 0.0007 2.00 (1.06–4.35) 0.03 1.86 (0.99–4.02) 0.05
Response
CR/PR (62)
NC (16) 1.75 (1.01–2.89) 0.04 1.76 (0.96–3.22) 0.07 1.79 (0.98–3.24) 0.06
Salvage cystectomy
No (61)
Yes (17) 0.81 (0.39–1.42) 0.49
XPC (Lys939Gln, A/C)
AA (21)
AC (37) 0.66 (0.18–2.38) 0.52
CC (13) 0.93 (0.19–3.79) 0.92
AC+CC (50) 0.87 (0.50–1.58) 0.62
XPD (Lys751Gln, A/C)
a
AA (62)
AC+CC (10) 0.68 (0.16–1.53) 0.41
XPG (Asp1104His, G/C)
GG (12)
GC (39) 1.56 (0.40–10.24) 0.55
CC (26) 1.50 (0.34–10.21) 0.61
GC+CC (65) 1.23 (0.65–3.11) 0.56
XRCC1 (Arg399Gln, G/A)
a
GG (47)
GA+AA (25) 0.51 (0.20–0.98) 0.04 0.70 (0.25–1.55) 0.40
XRCC3 (Thr241Met, C/T)
a
CC (60)
CT+TT (9) 0.75 (0.17–1.70) 0.54
Combined XPD and XRCC1
XPD AA and XRCC1 GG (40)
Other (32) 0.41 (0.16–0.79) 0.006 0.50 (0.19–0.97) 0.04
Total variant alleles in DNA repair genes
p3 (55)
43 (23) 0.51 (0.20–0.95) 0.03 0.77 (0.28–1.68) 0.53
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spolymorphisms have significant impacts on recurrence and recur-
rence-free survival time in superficial cancer. Moreover, Sak et al
(2005) indicated that high expression levels of APE1 and XRCC1 are
associated with improved cancer-specific survival following radical
radiotherapy in muscle-invasive bladder cancer. However, reports on
the associations between DNA repair gene polymorphisms and
clinical response or prognosis in muscle-invasive bladder cancer
patients treated with chemotherapy or radiotherapy are lacking.
We found a significant relationship between combined XPD and
XRCC1 genotypes and cancer-specific survival in muscle-invasive
bladder cancer patients treated with CRT. We also analysed stage
T3/T4 patients to assess the findings in confirmedly advanced
bladder tumours locally, because the staging on CT scan has
limited accuracy in some bladder cancer patients (Paik et al, 2000).
The relationship between the combined XPD and XRCC1
genotypes and cancer-specific survival was stronger in stage T3/
T4 patients. The combined genotypes might therefore be valuable
as an independent prognostic factor following CRT in muscle-
invasive bladder cancer. Bladder-conserving therapy using combi-
nations of chemotherapy, radiotherapy, and TUR has shown
promising results (Dunst et al, 2001; Ro ¨del et al, 2002), but not all
tumours respond. The ability to predict tumour sensitivity to CRT
would therefore be very helpful in patient selection for bladder
conservation therapy (Sak et al, 2005). In addition, most of the
molecular markers assessed for prognostic potential in bladder
cancer need tumour tissue samples and complex techniques
(Garcia del Muro et al, 2004; Matsumoto et al, 2004a,b;
Chakravarti et al, 2005), unlike the evaluation of germline genetic
polymorphisms, which requires little more than a peripheral blood
sample and standard PCR-based reactions, making these tests
potentially useful in the clinical setting (Gurubhagavatula et al,
2004).
In our series, the median dose of radiotherapy at 48.6Gy was
low compared with radical radiotherapy for bladder cancer.
However, Dunst et al (2001) stated that from radiobiological
considerations, 50Gy radiation should be able to control disease in
combination with complete transurethral surgery in the vast
majority of patients, and that this dose can be safely administered
in the pelvis, as is known from treatments of other pelvic
malignancies. They also indicated that the addition of (mainly
cisplatin based) chemotherapy improves local complete remission
rates irrespective of the radiation dose (Dunst et al, 2001).
Platinum compounds such as cisplatin form both intra- and
interstrand DNA adducts that result in bulky distortion of
DNA, destabilisation of the double helix, and inhibition of DNA
replication (Gurubhagavatula et al, 2004). These adducts are
responsible for the cytotoxicity of the drug, and clinical outcome
seems to be correlated with the level of platinum-DNA adducts
in the circulation (Reed et al, 1987; Bosken et al, 2002).
Additionally, these adducts are mainly repaired by the NER
pathway (Park et al, 2001). One hypothesis regarding DNA repair
capacity and muscle-invasive bladder cancer outcome is therefore
that suboptimal DNA repair within the tumour might actually lead
to decreased removal of platinum-DNA adducts, and thus,
increased clinical response and survival after platinum therapy
(Bosken et al, 2002).
Ionising radiation exposure damages cellular DNA in many
ways, requiring the concerted action of a number of DNA repair
enzymes to restore genomic integrity (Hu et al, 2001). The BER
and HRR pathways are particularly important with regard to this
(Thompson and West, 2000; Khanna and Jackson, 2001). As
oxidative base damage and strand breaks induced by ionising
radiation are repaired mainly by these two pathways, defective
repair activities might contribute to sensitivity to and improved
survival following radiotherapy. Thus, we selected DNA repair
genes: XPC, XPD, and XPG (involved in NER), XRCC1 (involved in
BER), and XRCC3 (involved in HRR), as the focus of this study.
Furthermore, the SNPs that we studied in these genes are thought
to be associated with different levels of DNA repair activity (Lunn
et al, 1999; Spitz et al, 2001; Matullo et al, 2003; Vodicka et al,
2004), and might explain interindividual differences in response
and prognosis after CRT for muscle-invasive bladder cancer. We
also analysed relationships between the combined XPD and
XRCC1 genotypes and clinical factors. As both XPD and XRCC1
genes are located close to each other at 19q13.2–13.3 (Mohren-
weiser et al, 1989), analysis of the combined XPD and XRCC1
genotypes might be meaningful with regard to specific haplotypes.
Yoon et al (2005) showed that the variant-type XRCC1
Arg399Gln genotype is associated with progression-free survival
advantage in non–small-cell lung cancer patients who have
received radiotherapy. Moreover, Hu et al (2001) indicated that
amino-acid substitution variants of XRCC1 and APE1 might
contribute to ionising radiation hypersensitivity. These results are
in accord with our findings that the wild-type genotypes of both
XPD and XRCC1 are associated with shorter cancer-specific
survival in muscle-invasive bladder cancer patients treated with
CRT. However, the results of Hu et al (2001) seem to contradict
those of Sak et al (2005) noted above. Sak et al (2005) stated that
one possible explanation is that the reduced expression of XRCC1
and APE1 merely reflects the poorly differentiated nature of
tumour cells in more aggressive tumours, and that cells from
aggressive tumours with extensive genomic instability could
contain chromosomal aberrations that result in the failure of
transcription of genes, including DNA repair genes, thus resulting
in lower protein expression of the gene products.
Gu et al (2005) analysed the association between the total
number of variant alleles in eight NER genes and the recurrence of
superficial bladder cancer. They emphasised that because the
prognosis of cancer patients likely involves multistep, multigenic
pathways, it is unlikely that any one single genetic polymorphism
would have a dramatic effect on clinical outcome, and that it is
important to take a pathway-based analysis of multiple poly-
morphic genes (Gu et al, 2005). Thus, we also analysed the
numbers of total variant alleles both in all DNA repair genes
studied and in NER genes. Although the numbers of total variant
alleles were significantly associated with recurrence and cancer-
specific survival (univariate analysis), no significant relationships
were found between specific combinations of variant alleles and
recurrence or cancer-specific survival (data not shown). The
number of total variant alleles was not significantly associated with
either recurrence after application of Bonferroni correction or
cancer-specific survival in multivariate analysis.
Table 4 (Continued)
Univariate model Multivariate model one Multivariate model two
Variable (n) Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value
Total variant alleles in NER genes
b
p2 (50)
42 (28) 0.83 (0.47–1.37) 0.48
TCC¼transitional cell carcinoma; CR¼complete response; PR¼partial response; NC¼no change; NER¼nucleotide excision repair.
aFor those polymorphisms with few
homozygous variant alleles, only the combined results of the heterozygous and homozygous variant alleles are shown.
bNER genes include XPC, XPD, and XPG.
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sGurubhagavatula et al (2004) showed that increasing numbers of
either XPD or XRCC1 variant alleles and a greater number of
variant alleles in combinations of both genes are associated with
shorter overall survival after therapy with platinum agents for non-
small-cell lung cancer. Further, Park et al (2001) indicated that
metastatic colorectal cancer patients with the wild-type XPD
genotype respond to 5-fluorouracil/oxaliplatin and have longer
median survival vs those with the variant genotypes. These results
are not consistent with our findings. This discrepancy may depend
on cancer type or therapies combined with radiation. Cisplatin has
been shown to enhance the cytotoxicity of radiation in both cell
culture and tumour-bearing animals, although the mechanisms of
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Figure 1 Kaplan–Meier cancer-specific survival curves for all muscle-
invasive bladder cancer patients treated with chemoradiotherapy. (A)
XRCC1 GG vs GAþAA genotypes; (B) patients stratified by combined
XPD and XRCC1 genotypes: XPD AA and XRCC1 GG vs other
genotypes; (C) patients stratified by the number of total variant alleles in
DNA repair genes: p3 vs 43.
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Figure 2 Kaplan–Meier cancer-specific survival curves for stage T3/T4
bladder cancer patients treated with chemoradiotherapy. (A) XRCC1 GG
vs GAþAA genotypes; (B) patients stratified by combined XPD and
XRCC1 genotypes: XPD AA and XRCC1 GG vs other genotypes; (C)
patients stratified by the number of total variant alleles in DNA repair
genes: p3 vs 43.
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chemoradiotherapy
Univariate model Multivariate model one Multivariate model two
Variable (n) Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value Risk ratio (95% CI) P-value
Age (years)
p68 (22)
468 (16) 1.07 (0.58–1.91) 0.81
Gender
Men (28)
Women (10) 0.79 (0.31–1.53) 0.51
Tumour grade
2 (10)
3 (28) 0.65 (0.37–1.20) 0.16
Histopathology
Pure TCC (32)
Other elements (6) 2.10 (0.98–3.92) 0.06
Cisplatin dose (mg)
o235 (18)
X235 (19) 1.58 (0.88–3.06) 0.13
Radiation dose (Gy)
o48.6 (13)
X48.6 (25) 3.03 (1.32–13.01) 0.005 2.18 (0.92–9.44) 0.08 2.14 (0.92–9.20) 0.08
Response
CR/PR (24)
NC (14) 1.28 (0.69–2.28) 0.42
Salvage cystectomy
No (25)
Yes (13) 0.54 (0.21–1.06) 0.08
XPC (Lys939Gln, A/C)
AA (10)
AC (18) 0.94 (0.21–4.79) 0.94
CC (6) 0.94 (0.12–5.69) 0.94
AC+CC (24) 0.97 (0.50–2.11) 0.93
XPD (Lys751Gln, A/C)
a
AA (27)
AC+CC (8) 0.0004 (0.00–0.79) 0.02 0.0006 (not calculated) 0.08
XPG (Asp1104His, G/C)
GG (6)
GC (21) 0.73 (0.16–5.02) 0.71
CC (11) 1.23 (0.24–8.93) 0.81
GC+CC (32) 0.96 (0.49–2.46) 0.92
XRCC1 (Arg399Gln, G/A)
a
GG (26)
GA+AA (9) 0.0004 (0.00–0.66) 0.005 0.0004 (not calculated) 0.02
XRCC3 (Thr241Met, C/T)
a
CC (29)
CT+TT (4) 0.92 (0.21–2.16) 0.87
Combined XPD and XRCC1
XPD AA and XRCC1 GG (20)
Other (15) 0.0003 (0.00–0.45) 0.0002 0.0003 (0.00–0.53) 0.0008
Total variant alleles in DNA repair genes
p3( 2 6 )
43 (12) 0.39 (0.09–0.88) 0.02 0.87 (0.20–2.08) 0.79
Total variant alleles in NER genes
b
p2( 2 2 )
42 (16) 0.85 (0.44–1.52) 0.59
TCC¼transitional cell carcinoma; CR¼complete response; PR¼partial response; NC¼no change; NER¼nucleotide excision repair.
aFor those polymorphisms with few
homozygous variant alleles, only the combined results of the heterozygous and homozygous variant alleles are shown.
bNER genes include XPC, XPD, and XPG.
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sthe interaction have not been defined (Schilsky, 1992). DNA repair
enzymes might decrease the synergistic effects of combination of
cisplatin and radiation. The reason for the discrepancy could be
clarified by investigating the relationship between the genotypes of
DNA repair genes and outcomes in bladder cancer patients treated
with other modalities such as platinum-based systemic chemother-
apy alone and radiotherapy alone. Additionally, to remove gene
prevalence as a confounding event, validation with an independent
sample set is needed, as is a sample set from a different ethnic
background.
In conclusion, combined XPD and XRCC1 genotypes were
shown to be associated with cancer-specific survival in muscle-
invasive bladder cancer patients treated with CRT. The results
suggest that these genotypes might be prognostic factors following
CRT in bladder cancer, helping patient selection for bladder
conservation therapy. However, with the limited sample size, our
results allow only preliminary conclusions, but warrant larger
studies to further test the prognostic significance of the genotypes
of DNA repair genes in muscle-invasive bladder cancer patients
treated with CRT.
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